MUC16 and cancer: For benign vs. stage I and II cancer (n = 53), the sensitivity of CTC detection was 100% (zero false negative rate), bettering the sensitivities of the other modalities (ROMA, 70.0%; CA-125, 70.0%; RMI, 50.0%; and CT/MRI, 90.0%).